First Quarter Updates, In Brief
Executive Summary
Launch news was an important factor for Bristol-Myers in the first quarter and dominated the biotech sector, with several companies reporting better-than-expected early performances of new products, although for Lilly, the news was all about upcoming data read-outs.
You may also be interested in...
Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia
Statins represent a high standard of care for managing high blood cholesterol, bolstered by a strong evidence base, but new targets like PCSK9 and CETP are nevertheless stealing the spotlight nowadays. Whether new drugs, if they make it to market, will be used beyond narrow, targeted population segments is uncertain and will depend on results from large-scale outcomes studies showing significant efficacy and, importantly, reassurance of a solid safety profile.
Icahn Turns Up The Heat On Amylin, Urges Board To Sell
The activist investor, previously involved in buyouts at ImClone, Biogen Idec and Elan, as well as a proxy fight at Genzyme, scolds Amylin’s board for lack of transparency on purported Bristol offer and asserts the biotech is not positioned to maximize the market potential of Bydureon.
Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.